Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryAetna Acute Ischemic Stroke Coverage & Prior Auth …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0789

    Acute Ischemic Stroke Treatments

    Customize your policy alerts

    Sign up for Aetna Policy 0789 alerts

    Get alerted when Policy 0789 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and coverage for selected endovascular, pharmacologic, and adjunctive treatments for acute ischemic stroke (AIS) and medically refractory delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage for Aetna members.

    Policy Summary
    PayerAetna
    PolicyAcute Ischemic Stroke Treatments
    Policy CodePolicy 0789
    Change TypeNo material change
    Effective DateJul 10, 2009
    Last ReviewNov 7, 2023
    Next Review DateSep 12, 2024
    Key ActionObtain and document prior authorization and clinical imaging showing large-vessel anterior circulation occlusion, salvageable tissue, and timing when requesting endovascular stent retriever therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 hwindow for endovascular retrievable stent thrombectomy
    8 hmechanical thrombectomy study window
    3–4.5 hIV tPA window
    82%reported max recanalization rate
    2009-07-10Policy effective

    Coverage Criteria and Evidence Summary

    Endovascular stent retriever therapy (medically necessary)

    Endovascular therapy with a retrievable stent is considered medically necessary when ALL of the following are met:

    Stent retriever criteria: 1) Acute ischemic stroke with occlusion of the anterior circulation (middle cerebral artery trunk or its branches or internal carotid artery). 2) Imaging demonstrates evidence of salvageable brain tissue (e.g., perfusion imaging or ASPECTS criteria). 3) Retrieval is performed within 12 hours of stroke onset.time <= 12 hours

    Applies to retrievable stent devices (e.g., Solitaire FR, Trevo)

    Intra-arterial spasmolytic/calcium-channel blocker infusion (medically necessary)

    Intra-arterial infusion of spasmolytics or calcium-channel blockers is considered medically necessary when ALL of the following are met:

    IA spasmolytic infusion criteria: 1) Patient has medically refractory symptomatic delayed cerebral ischemia (cerebral vasospasm) after aneurysmal subarachnoid hemorrhage. 2) Infusion is delivered into intracranial arteries for treatment of the vasospasm (selective intra-arterial vasodilator therapy).
    Policy Summary
    PayerAetna
    PolicyAcute Ischemic Stroke Treatments
    Policy CodePolicy 0789
    Change TypeNo material change
    Effective DateJul 10, 2009
    Last ReviewNov 7, 2023
    Next Review DateSep 12, 2024
    Key ActionObtain and document prior authorization and clinical imaging showing large-vessel anterior circulation occlusion, salvageable tissue, and timing when requesting endovascular stent retriever therapy.
    SourceLink
    On This Page
    Coverage Criteria and Evidence SummaryBilling Codes and Time WindowsPrior Authorization, Documentation, and Provider ResponsibilitiesClinical Background and ContextDefinitions and Key TermsPolicy Dates and References
    clinical refractory vasospasm

    Examples: papaverine, intra-arterial nicardipine; used when hemodynamic augmentation fails

    Experimental / Investigational (Not Covered)

    The following procedures and therapies are considered experimental and investigational (therefore not covered):

    Experimental/investigational list: Acute intracranial stenting with concomitant tirofiban; cerebrolysin; defibrinogen therapy (ancrod, batroxobin); erythropoietin; glycoprotein IIb/IIIa antagonists (e.g., tirofiban) for AIS; governor vessel acupuncture; hypothermia for AIS; mesenchymal stem cells or mesenchymal stem cell–conditioned medium; microbubbles combined with ultrasound sonothrombolysis; minocycline; normobaric oxygen therapy; sphenopalatine ganglion stimulation; transcranial ultrasound devices (e.g., CLOTBUST-HF); transdermal glyceryl trinitrate; statins for AIS (as listed in policy).listed therapies

    Identified as experimental/investigational in policy; not covered for indications listed

    Stent retriever thrombectomy — AHA/ASA 2015 Class I criteria

    Endovascular therapy with a stent retriever is recommended when ALL of the following are met (per AHA/ASA 2015; Class I; Level A):

    Stent retriever thrombectomy — Class I criteria: 1. Pre-stroke modified Rankin Scale (mRS) score 0 to 1; 2. Acute ischemic stroke receiving IV alteplase (r‑tPA) within 4.5 hours when eligible per guidelines; 3. Causative occlusion of the internal carotid artery or proximal MCA (M1); 4. Age ≥18 years; 5. NIHSS ≥6; 6. ASPECTS ≥6; 7. Treatment can be initiated (groin puncture) within 6 hours of symptom onset.all

    Per Powers et al., 2015 AHA/ASA guideline criteria

    Endovascular therapy when IV tPA contraindicated or for other vessel occlusions

    Endovascular therapy may be reasonable (lower level evidence) when ALL of the following are met:

    Endovascular therapy when IV tPA contraindicated or for other vessel occlusions: 1. Contraindication to IV r‑tPA or IV r‑tPA not administered; 2. Carefully selected anterior circulation large‑vessel occlusion (or selected M2/M3, ACA, vertebral, basilar, PCA occlusions based on clinical judgment and imaging); 3. Treatment with stent retriever can be initiated within 6 hours of symptom onset; 4. Clinical judgement supports likelihood of benefit given infarct core and collateral status.all

    Based on lower-level evidence per Powers et al., 2015

    Endovascular therapy for symptomatic, medically refractory cerebral vasospasm

    Endovascular treatment for cerebral vasospasm is considered reasonable when ALL of the following are met:

    Rescue therapy for symptomatic vasospasm: Symptomatic cerebral vasospasm causing delayed cerebral ischemia that is refractory to maximal medical management (e.g., hemodynamic augmentation, oral nimodipine).all

    Guidelines support angioplasty and/or selective intra-arterial vasodilator therapy as reasonable rescue therapy; prophylactic angioplasty is not recommended

    Coverage-relevant evidence conclusions

    Summary coverage-relevant conclusions from evidence:

    Nimodipine for aneurysmal SAH: Oral nimodipine (typical 60 mg every 4 hours) is indicated after aneurysmal subarachnoid hemorrhage based on evidence of benefit; intravenous calcium antagonists are not recommended for routine practice.

    Evidence summary supports nimodipine use

    Mechanical thrombectomy devices achieve higher recanalization rates for large‑vessel occlusion; randomized trials historically had mixed results versus IV tPA, though newer stent‑retriever trials demonstrate improved recanalization and promising signals for clinical outcomes; definitive generalized superiority was evolving at time of guideline assessments.

    Recanalization benefits noted; functional outcome evidence variable

    Adjunct/experimental therapies: Therapies such as intra-arterial magnesium/nicardipine, tirilazad, sonothrombolysis, therapeutic hypothermia, transdermal GTN have mixed or preliminary evidence; tirilazad did not improve outcomes; GTN showed no overall 90‑day benefit though possible very‑early (<6 h) subgroup effect.

    Interpretive evidence summaries

    Therapy-specific evidence summaries

    Coverage considerations based on presented evidence:

    Transdermal glyceryl trinitrate (GTN): GTN lowered blood pressure when started within 48 hours but did not improve 90‑day functional outcome in the overall ENOS trial; a pre‑specified subgroup randomized within 6 hours suggested benefit.

    Subgroup hypothesis-generating

    Cerebrolysin: Multiple RCTs and meta-analyses have not demonstrated clinical benefit for functional outcomes and moderate‑quality evidence suggests possible increased serious adverse events; routine use is not supported.

    Considered investigational/not medically necessary

    Erythropoietin (EPO): Evidence is inconsistent and meta-analysis suggested increased mortality when combined with rtPA; use raises safety concerns.

    Not recommended outside trials

    Normobaric oxygen (NBO): Most trials of low‑flow NBO show no benefit; a single small RCT suggested high‑flow NBO after re‑canalization may improve outcomes, but overall evidence insufficient for routine use.

    Further study needed

    Defibrinogen therapy: Evidence is limited to case series with methodological limitations; insufficient high‑quality evidence to support routine coverage.

    Investigational

    Microbubbles + ultrasound sonothrombolysis: Clinical results heterogeneous and safety data limited; AHA guidelines do not recommend sonothrombolysis as adjuvant to IV tPA.

    Guideline‑disfavored

    Microstent retrievers for distal occlusions: Small series demonstrate feasibility and high reperfusion rates for selected distal occlusions; larger studies needed to establish clinical benefit.

    Limited evidence, specialized use only

    Minocycline: Pooled RCT data suggest a possible benefit in AIS subgroups for 3‑month functional outcomes, but evidence is limited and further RCTs are required.

    Promising but investigational

    Evidence summaries and interpretive criteria (informational)

    Background evidence summaries and investigational status; no explicit coverage criteria are provided in these sections. Key interpretive points for clinicians:

    Minocycline: Pooled RCT evidence (7 trials, 426 patients) suggests a favorable trend for 3‑month functional independence in AIS subgroup without increased adverse events; further RCTs needed.

    Informational

    Statins (Simvastatin): Small randomized trial found improvements in biomarkers and clinical scales at 90 days with simvastatin but no dose‑response difference; findings preliminary and not definitive for dosing recommendations.

    Informational

    Tenecteplase: Meta‑analyses and trials indicate tenecteplase may provide superior early neurological improvement versus alteplase with similar 90‑day outcomes; ongoing trials will clarify role and dosing.

    Informational

    Sphenopalatine Ganglion Stimulation (SGS): Pivotal randomized trial did not show overall benefit in primary endpoint but suggested a positive signal in patients with cortical involvement; safety acceptable; not established as standard practice.

    Investigational outside select contexts

    Tirofiban: Systematic reviews/meta‑analyses report mixed findings on safety and efficacy; some analyses show increased fatal ICH with IA administration while others show mortality reduction in select settings; functional benefits inconsistent and context‑dependent.

    Use uncertain; evidence context dependent

    Acute intracranial stenting with concomitant tirofiban: Small single‑center series report feasibility and acceptable mid‑term patency in intracranial artery dissection, but evidence is limited by small numbers and retrospective design.

    Investigational and not generalizable

    Acute stenting + tirofiban — evidence context

    Acute intracranial stenting with concomitant IV tirofiban:

    Eligibility in reported series: Patients with intracranial artery dissection undergoing acute stenting in the setting of AIS with a small ischemic core; selection and outcomes derived from a retrospective single‑center series (n=7).

    Evidence limited; reported parent artery patency 85.7% and mRS ≤2 in 71.4% at 3 months in the series

    Governor vessel acupuncture — reported findings

    Governor vessel acupuncture (GV Ac):

    Reported intervention: GV acupuncture alone or combined with conventional neurological therapy versus control acupuncture or conventional therapy; outcomes included BI, mRS, NIHSS, ADL in RCTs largely conducted in China.

    Systematic review of 18 RCTs (1,543 patients) suggested improvements but trials had methodological limitations and limited generalizability

    Thrombectomy ± IV alteplase — evidence synthesis

    Mechanical thrombectomy with vs without IV thrombolysis — trial evidence:

    Trial outcomes summary: Randomized trials (e.g., Direct‑MT, Yang et al., Suzuki et al., Zi et al.) comparing thrombectomy alone versus thrombectomy plus IV alteplase report heterogeneous results: some trials met non‑inferiority thresholds while others did not; safety outcomes were often similar though reperfusion rates and ICH rates varied by study.

    Interpretation depends on non‑inferiority margins, alteplase dosing, populations, and workflow times

    Common eligibility in trials: Patients with anterior‑circulation large‑vessel occlusion within 4.5 hours eligible for IV thrombolysis were commonly enrolled; trials used differing alteplase doses and non‑inferiority margins.onset-to-treatment ≤4.5 hours

    Documentation of times and alteplase dosing important for applicability

    Fingolimod adjunct — preliminary evidence

    Fingolimod plus standardized treatment:

    Reported findings: Meta‑analysis of 5 small RCTs (228 subjects) reported higher proportion achieving mRS 0–1 at 90 days with fingolimod plus standard treatment and decreased infarct growth, but trials were small, methodologically limited, and predominantly from China.

    Preliminary evidence; larger trials needed

    MSC-CM — preclinical data

    Mesenchymal stem cell–conditioned medium (MSC-CM):

    Preclinical evidence: Preclinical MCAO studies (systematic review of 15 datasets) found MSC‑CM improved functional recovery and reduced infarct volume; therapeutic time window important.

    Preclinical data only; clinical translation not established

    PTAS for BAS — candidate selection and outcomes

    Percutaneous transluminal angioplasty with stenting (PTAS) for basilar artery stenosis (BAS):

    Indications in reviewed series: PTAS has been reported for acutely symptomatic severe BAS or elective PTAS for severe (≥50%–70%) symptomatic BAS refractory to dual antiplatelet therapy; selection in pooled cohorts emphasized high‑grade stenosis (median baseline ~81%).stenosis >=50%-70%

    Technical success often high but clinical outcomes and complication risks variable; randomized trials lacking

    PTAS candidate selection (evidence-based criteria)

    Descriptive criteria from cited studies and guidance (not formal coverage decision language):

    Elective PTAS for basilar artery stenosis: Patient with severe (≥50%–70%) symptomatic basilar artery stenosis who remains symptomatic or at risk despite optimal medical therapy (refractory to dual antiplatelet therapy); lesion characteristics suitable for angioplasty/stenting; procedure performed electively at an experienced center.severity >=50%-70%

    Based on pooled cohort analyses and expert guidance; randomized evidence lacking

    Endovascular recanalization candidate selection

    Descriptive criteria from a single-center SNOVA series:

    Endovascular recanalization for symptomatic non-acute vertebrobasilar occlusion: Patient with symptomatic non‑acute occlusion of vertebra‑basilar artery, lesion amenable to endovascular recanalization, and acceptable procedural risk profile; selection described in single‑center series reporting high technical success (92%) with peri‑procedural complication and mortality risks.none specified numerically

    Series reports mean lesion length and outcomes; evidence limited and single‑center

    The policy distinguishes medically necessary use of intra‑arterial spasmolytics or calcium‑channel blockers from other indications. Infusion into intracranial arteries is considered medically necessary only for patients with medically refractory symptomatic delayed cerebral ischemia (vasospasm) after aneurysmal subarachnoid hemorrhage. Infusion for other indications is identified in the policy scope as experimental/investigational and not covered.

    Guideline guidance and the policy caution against routine prophylactic angioplasty: international guidance either recommends against routine prophylactic angioplasty or issues no recommendation. Endovascular rescue (angioplasty or intra‑arterial vasodilators) is described as reasonable only for symptomatic, medically refractory vasospasm, and the timing and triggers for prophylactic or routine angioplasty remain unclear.

    The evidence synthesis indicates that tirilazad did not improve mortality or poor outcome when added to standard care for aneurysmal SAH, and therefore is not effective for that indication. Likewise, the document states that intravenous calcium antagonists are not recommended for routine practice, with oral nimodipine remaining the only calcium‑channel antagonist supported for post‑SAH use.

    The American Heart Association guidance cited in the policy does not recommend the use of sonothrombolysis (microbubbles combined with ultrasound) as an adjunct to IV fibrinolysis. The policy therefore treats sonothrombolysis as a guideline‑disfavored adjunctive therapy pending stronger evidence of safety and clinical benefit.

    The policy notes uncertainty in guideline statements regarding the safety and efficacy of intravenous glycoprotein IIb/IIIa inhibitors (e.g., tirofiban) administered during endovascular stroke treatment. While small case series of acute stenting with concomitant tirofiban are described, the document highlights methodological limitations and does not provide explicit payer‑level exclusions for IV IIb/IIIa agents in the excerpts reviewed.

    Evidence for governor vessel (GV) acupuncture is limited to randomized trials performed in China. The policy and cited systematic review note methodological limitations (risk of bias, lack of blinding, single‑country data) that restrict generalizability and preclude routine coverage based on current evidence.

    Many interventions reviewed lack randomized trial evidence that is broadly generalizable. The policy emphasizes that numerous studies are retrospective, single‑center, or population‑specific (for example, cohorts from China), limiting applicability of results to wider patient populations and supporting continued classification of such approaches as investigational outside specific study contexts.

    The policy explicitly lists multiple procedures and treatments as experimental/investigational (not covered) for the indications addressed. Examples called out in the scope and coding sections include acute stenting with concomitant tirofiban, cerebrolysin, defibrinogen therapies (ancrod, batroxobin), erythropoietin, glycoprotein IIb/IIIa antagonists, sphenopalatine ganglion stimulation, transcranial ultrasound devices (CLOTBUST‑HF), transdermal glyceryl trinitrate, microbubbles with ultrasound sonothrombolysis, and normobaric oxygen therapy.

    Use of mechanical embolectomy devices other than modern stent retrievers, or expansion of neurothrombectomy outside clinical trial settings, is described as premature. The policy cites prior uncertainty about whether older devices provided net clinical benefit over IV rt‑PA and recommends that broader adoption be supported by randomized data before routine coverage is expanded.

    Randomized trials cited in the policy have not uniformly demonstrated that endovascular therapy is superior to IV tPA for acute ischemic stroke. Assessments summarized in the document therefore caution that routine, unrestricted use of endovascular approaches may be premature and that some randomized trials were stopped for futility, supporting a cautious coverage stance outside guideline‑specified indications.

    The policy summarizes systematic reviews and randomized trials showing that cerebrolysin has not demonstrated consistent clinical benefit for functional recovery after acute ischemic stroke and that some analyses suggest an increased risk of serious adverse events. As a result, routine administration of cerebrolysin is not supported by the available RCT evidence and is considered investigational or not medically necessary.

    Sphenopalatine ganglion stimulation (SGS) is not established as standard management. A large randomized sham‑controlled trial reported no significant benefit in the overall population but a positive signal in a cortical‑involvement subgroup; trial results are therefore mixed and SGS is considered investigational outside of specific trial contexts.

    Several interventions discussed in the policy are supported only by small single‑center series, preliminary meta‑analyses with small sample sizes, or preclinical data. Examples include acute intracranial stenting with concomitant tirofiban (small retrospective series), fingolimod adjunctive therapy (small RCTs/meta‑analysis), and mesenchymal stem cell–conditioned medium (preclinical datasets), which the policy identifies as requiring larger, higher‑quality trials before routine coverage.

    Trials that established benefit of mechanical thrombectomy largely excluded posterior circulation strokes, limiting generalizability. The document notes that endovascular interventions for vertebrobasilar occlusions remain of uncertain benefit except in selected populations and when performed at centers with appropriate expertise, and randomized evidence for posterior circulation disease is limited.

    Billing Codes and Time Windows

    Covered CPT Codes (if selection criteria met)CPTCovered
    37184Primary percutaneous transluminal mechanical thrombectomy, noncoronary, arterial or arterial bypass graft, including fluoroscopic guidance and intraprocedural pharmacological thrombolytic injection(s); initial vessel.
    37185Second and all subsequent vessel(s) within the same vascular family (List separately in addition to code for primary mechanical thrombectomy procedure).
    61645Percutaneous arterial transluminal mechanical thrombectomy and/or infusion for thrombolysis, intracranial, any method, including diagnostic angiography, fluoroscopic guidance, catheter placement, and intraprocedural pharmacological thrombolytic injection(s).
    CPT Codes Not Covered for Indications ListedCPTNot Covered
    38206Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous.
    38232Bone marrow harvesting for transplantation; autologous.
    38241Hematopoietic progenitor cell (HPC); autologous transplantation.
    97810Acupuncture
    97811Acupuncture
    97812Acupuncture
    97813Acupuncture
    97814Acupuncture
    HCPCS/J Codes Not Covered for Indications Listed (experimental/investigational therapies)HCPCSNot Covered
    J0885Injection, epoetin alfa, (for non-ESRD use), 1000 units.
    J0887Injection, epoetin beta, 1 microgram, (for ESRD on dialysis).
    J0888Injection, epoetin beta, 1 microgram, (for non ESRD use).
    J2265Injection, minocycline HCl, 1 mg.
    J3246Injection, tirofiban HCl, 0.25 mg.
    Q4081Injection, epoetin alfa, 100 units (for ESRD on dialysis).
    Other HCPCS codes related to the CPBHCPCS
    C1757Catheter, thrombectomy/embolectomy.
    C1876Stent, non-coated/non-covered, with delivery system.
    C1884Embolization protective system.
    C1887Catheter, guiding (may include infusion/perfusion capability).
    ICD-10 Codes Covered if Selection Criteria Are MetICD-10Covered
    I63.00-I63.9Cerebral infarction [acute ischemic stroke].
    I67.82Cerebral ischemia [medically refractory symptomatic delayed cerebral ischemia].
    I67.841-I67.848Cerebral vasospasm and vasoconstriction [medically refractory symptomatic delayed cerebral ischemia].
    Treatment time windows referenced in policy and background studies — key time windows for reperfusion therapies
    Endovascular stent retriever windowRetrieval performed within 12 hours after stroke onset (policy medical necessity).
    Many mechanical thrombectomy studiesTreatment windows commonly reported up to 8 hours after symptom onset (e.g., MERCI, Multi-MERCI).
    Intravenous tPA windowIV tPA is administered within a narrow time window commonly ≤3–4.5 hours after stroke onset (background context).
    Basilar artery stenosis severity — median baseline severity reported in pooled studies
    Definition of severe BAS in pooled studiesSevere basilar artery stenosis described as greater than or equal to 50%–70%; pooled studies reported a median baseline stenosis of 81%.
    Degree of stenosis threshold — typical stenosis thresholds referenced (>=50% to 70%)
    Typical stenosis thresholds>= 50% to 70% stenosis commonly used to define severe basilar artery stenosis in reviewed PTAS series.
    Median baseline value citedMedian baseline basilar artery stenosis in pooled cohorts was 81% (range 53%–99%).
    Post-intervention residualMedian post-intervention residual stenosis reported as 13% (range 0%–75%).

    Prior Authorization, Documentation, and Provider Responsibilities

    Prior Authorization

    Prior authorization: thrombectomy criteria

    Prior authorization may be required for mechanical thrombectomy (endovascular thrombectomy) for acute ischemic stroke. Prior authorization requests should confirm key clinical and imaging criteria consistent with guideline-based selection for thrombectomy.

    • Confirm anterior circulation proximal large-vessel occlusion (internal carotid artery or MCA M1 ± M2) or other treated occlusion per plan guidance
    • Document evidence of salvageable brain tissue (advanced perfusion imaging showing small core/target mismatch) and ASPECTS ≥6 where applicable
    • Establish NIHSS ≥6 and pre-stroke mRS 0–1 when applicable to selection criteria
    • Treatment initiated (groin puncture) within recommended time window (typically ≤6 hours; consider extended-window criteria per imaging up to 12–24 hours where supported)
    • If IV alteplase was administered, document dosing and timing relative to thrombectomy (onset-to-treatment and door-to-puncture times)
    Prior Authorization

    Prior authorization for endovascular therapy

    Prior authorization may be requested or required for endovascular therapies beyond standard, guideline-supported indications. For interventions where randomized trials have not shown clear superiority to IV tPA or where evidence is limited, prior authorization should document rationale and supporting clinical/imaging data.

    • Specify the device/technique planned (stent retriever vs aspiration vs other device) and evidence of device-specific benefit if available
    • Provide imaging confirming proximal occlusion, infarct core size, and collateral status supporting endovascular approach
    • Document contraindications to IV thrombolysis or failure of IV therapy if endovascular therapy is being offered as alternative
    Denial Risk

    Cerebrolysin prior authorization guidance

    Cerebrolysin is considered experimental/investigational for acute ischemic stroke and prior authorization is expected to include documentation of investigational status and clinical justification if requested. Trials and systematic reviews have not demonstrated clear functional benefit and have signaled possible increased serious adverse events.

    • State that Cerebrolysin is listed as investigational in the policy and is generally not covered
    • Include trial data or rationale only for exceptional/clinical-trial enrollment situations
    Note

    Prior authorization: none specified

    For several investigational interventions (for example: acute stenting with concomitant tirofiban, microbubbles with ultrasound sonothrombolysis, transdermal glyceryl trinitrate for acute AIS, normobaric oxygen, many neuroprotective agents), the policy does not specify routine prior-authorization pathways — these are considered experimental/investigational and may be denied. Providers must follow plan provisions and submit full clinical rationale when seeking coverage.

    • Treatments labeled experimental/investigational are at high risk of denial if submitted without compelling, plan-approved evidence or clinical trial context
    • Prior authorization is determined by the member's plan and contract terms; contact plan for case-specific guidance
    Prior Authorization

    PTAS — prior authorization expectations

    Percutaneous transluminal angioplasty with stenting (PTAS) for basilar artery stenosis is generally considered only for severe, symptomatic basilar artery stenosis refractory to optimal medical therapy; prior authorization requests should document severity and prior medical management.

    • Document percent stenosis (typically ≥50–70%) and location (basilar artery)
    • Provide history of symptomatic events (TIA/stroke) attributable to the lesion
    • Confirm failure or intolerance of dual antiplatelet therapy and other optimal medical management prior to PTAS request
    Note

    Prior authorization determined by member plan

    Whether prior authorization is required and the specific administrative process for any procedure is ultimately determined by the member’s plan benefits. Providers must follow the member’s plan provisions and check payer-specific prior authorization portals or contact the plan for verification.

    • Verify member eligibility and benefit coverage prior to scheduling
    • Follow Aetna plan-specific prior authorization procedures (portal/phone) and include required documentation
    Denial Risk

    Denial risk for experimental/investigational treatments

    Procedures and therapies designated as experimental or investigational in this policy are at elevated risk of denial. Submit comprehensive clinical documentation only in exceptional circumstances (e.g., clinical trial participation or prior authorization appeals with new evidence).

    • Common investigational items include: Cerebrolysin, acute stenting with tirofiban, EPO, microbubble sonothrombolysis, stem cell therapies, hypothermia for AIS
    Denial Risk

    Guideline-disfavored therapy

    Some therapies are specifically disfavored by clinical guidelines (e.g., sonothrombolysis as an adjunct to IV fibrinolysis). Requests for such therapies should include guideline-based justification or be considered non-covered.

    • AHA/ASA guidance advises against routine use of sonothrombolysis as an adjunct to IV fibrinolysis
    • Document any compelling new evidence or trial enrollment if seeking coverage for guideline-disfavored therapies
    Note

    No explicit coverage authorization or pr

    The policy background includes no universal statement that prior authorization is required for all covered interventions; however, administrative notes indicate that safety concerns and evidentiary limitations exist. Providers should not assume automatic coverage and must follow plan-specific authorization rules.

    • Absence of an explicit coverage authorization statement in the CPB does not equate to coverage — verify with the payer
    • Clinical Policy Bulletins are partial descriptions and plan terms govern coverage decisions
    Documentation Required

    Candidate selection for PTAS

    Candidate selection for PTAS should be carefully documented: PTAS has been used for severe symptomatic basilar artery stenosis in patients who remain symptomatic despite medical therapy.

    • Indication typically severe (≥50–70%) symptomatic BAS with recurrent ischemic events
    • Preferential use of Wingspan or comparable devices documented in literature; include device planned
    Documentation Required

    Documentation of severity and refractory status

    Prior authorization requests must include documentation of percent stenosis and failure of medical therapy for PTAS candidates. The plan requires objective evidence of severity and refractory status before approving invasive interventions.

    • Provide angiographic or CTA/MRA measurements of baseline stenosis and post-treatment targets
    • Include prior antiplatelet regimen details and documentation of continued ischemic events despite optimal therapy
    Documentation Required

    Clinical documentation requirements

    Clinical documentation requirements for endovascular and investigational therapies should include baseline neurologic assessment, imaging confirming occlusion and salvageable tissue, and prior therapies attempted.

    • Baseline NIHSS and pre-stroke mRS
    • Imaging modality and findings (CT/CTA, CT perfusion, MRI/DWI, perfusion maps) demonstrating occlusion, infarct core, and penumbra
    • Documentation of contraindications to IV thrombolysis if applicable
    Documentation Required

    Required clinical documentation for thrombectomy

    Required clinical documentation for thrombectomy prior authorization includes imaging demonstrating a proximal large-vessel occlusion, evidence of salvageable tissue (small infarct core / target mismatch), and a relatively small infarct core on perfusion imaging or ASPECTS.

    • CT/CTA or MR/MRA confirming occlusion site
    • Perfusion imaging quantifying core and penumbra (e.g., core <70 mL or per local protocol)
    • ASPECTS score where applicable and NIHSS score
    Documentation Required

    Suggested documentation elements

    Suggested documentation elements for endovascular procedures include details of the occlusion confirmation modality, device to be used, and timing metrics (onset-to-puncture and onset-to-recanalization).

    • Modality used to confirm vessel occlusion (CTA, MRA, DSA) and representative images in the record
    • Planned device/technique (stent retriever, aspiration, combined), device model if known
    • Time metrics: symptom onset, arrival, imaging, IV tPA bolus (if given), groin puncture, and recanalization times
    Documentation Required

    Timing and outcome documentation

    Timing and outcome documentation should be available in the medical record for prior authorization and post-procedure review. Include onset-to-treatment intervals and standard outcome measures used in trials.

    • Onset-to-door, door-to-needle (IV tPA), door-to-puncture, onset-to-recanalization times
    • Outcome measures: NIHSS, modified Rankin Scale (mRS) at discharge and 90 days, Barthel Index where available
    • Document any symptomatic intracerebral hemorrhage or procedural complications
    Documentation Required

    Documentation expectations (background)

    Documentation expectations from clinical trials and guideline context: records should include trial-like outcome measures (mRS, NIHSS, BI), intracerebral hemorrhage rates, mortality, and procedural details to support medical necessity determinations.

    • Include follow-up documentation of 90-day functional outcomes when available
    • Record any device-related adverse events, ICH, or re-occlusion events
    Step Therapy

    Stepwise treatment context

    When mechanical thrombectomy is considered, document prior use or ineligibility for IV thrombolysis (stepwise treatment context). Provide evidence if endovascular therapy is being used as an adjunct or alternative.

    • State whether IV alteplase was administered, contraindicated, or unable to achieve reperfusion
    • Show prior non-invasive therapies attempted and responses
    Step Therapy

    Step before higher-cost or experimental options

    Consider established, lower-cost, or guideline-supported alternatives before higher-cost or experimental options. Prior authorization reviewers will expect documentation that standard therapies were attempted or contraindicated prior to experimental interventions.

    • Document failure or contraindication to IV tPA or optimal medical therapy before escalation
    • For therapies with mixed evidence (e.g., EPO), provide rationale and prior treatment course
    Step Therapy

    No step-therapy pathways are defined

    The policy does not define formal step-therapy pathways for many investigational or emerging treatments. Providers should not assume a standardized step-therapy sequence and must document clinical rationale when deviating from standard care.

    • Tenecteplase and other alternatives are discussed in literature but not codified into formal step-therapy requirements in this CPB
    • For PTAS, step-therapy context generally describes PTAS after failure of dual antiplatelet therapy

    Clinical Background and Context

    Background: Acute ischemic stroke (AIS) is a leading cause of death and disability. Standard acute management includes intravenous thrombolysis with tPA administered within a narrow time window (commonly ≤ 3–4.5 hours) for eligible patients. Endovascular approaches, including mechanical thrombectomy with stent retrievers, are used for large‑vessel occlusions and may extend treatment opportunities for selected patients.

    Definitions and Key Terms

    Anterior circulation occlusion — definition and examples
    DefinitionOcclusion of the middle cerebral artery trunk or its branches or the internal carotid artery.
    Examples (anterior circulation)Middle cerebral artery (M1/M2/M3) occlusions and internal carotid artery occlusion are cited as anterior circulation large-vessel occlusions.
    Relevance to therapyPresence of anterior circulation occlusion plus imaging evidence of salvageable tissue is a criterion for stent retriever thrombectomy when other criteria are met.
    Salvageable tissue on imaging — definition and imaging examples
    DefinitionImaging evidence (e.g., CT or MR perfusion criteria) indicating brain tissue at risk but potentially recoverable with reperfusion therapy.
    Imaging examplesCT perfusion or MRI perfusion/diffusion mismatch and small ischemic core on ASPECTS are referenced as indicators of salvageable tissue.
    Use in selectionEvidence of salvageable tissue on imaging is required for endovascular stent retriever therapy per policy criteria.
    ASPECTS — definition and referenced threshold (ASPECTS >=6)
    Definition (ASPECTS)Alberta Stroke Program Early CT Score (ASPECTS) is an imaging metric used to estimate ischemic core size on CT; higher scores indicate smaller core.
    Referenced thresholdASPECTS ≥6 is cited in guideline and trial criteria as a threshold for considering stent retriever thrombectomy.
    Role in selectionASPECTS used to identify patients with a small infarct core suitable for endovascular reperfusion; linked to improved outcomes when revascularization achieved.
    mRS — modified Rankin Scale definition and use as outcome
    DefinitionModified Rankin Scale (mRS) is a 0–6 scale measuring disability/outcome; 0–2 typically denotes functional independence.
    Use as outcomemRS at 90 days is a common primary functional outcome in stroke trials (proportion with mRS 0–2 used to define functional independence).
    Use in trials citedMultiple thrombectomy and thrombolysis trials use 90-day mRS distribution or mRS 0–2 as primary or key secondary endpoints to assess benefit.
    Nimodipine — role after aneurysmal SAH and typical dosing context
    Role after aneurysmal SAHOral nimodipine is indicated after aneurysmal subarachnoid hemorrhage to reduce vasospasm-related complications based on systematic review evidence.
    Typical dosingTypical oral dosing cited: 60 mg every 4 hours.
    IV administration noteIntravenous administration of calcium antagonists is not recommended for routine practice per available evidence.
    Mechanical thrombectomy — definition and example devices
    DefinitionMechanical thrombectomy is endovascular mechanical clot removal using devices such as Merci, Penumbra, TREVO, and Solitaire to recanalize large proximal cerebral artery occlusions.
    Example devicesDevices cited include Merci retriever, Penumbra system, TREVO, and Solitaire FR stent retrievers.
    Clinical contextUsed for large-vessel occlusion, as stand-alone therapy or adjunct to IV tPA, often beyond IV thrombolysis window or when IV tPA contraindicated.
    Cerebrolysin — definition and investigational status
    DefinitionCerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue with proposed neuroprotective/neurotrophic properties.
    Investigational statusMultiple RCTs and meta-analyses have not demonstrated clear functional benefit for AIS; routine use is considered experimental/investigational in the policy.
    Evidence summaryA Cochrane review identified 6 RCTs (1,501 participants) with unclear risk of bias and no consistent demonstration of clinical benefit.
    Normobaric oxygen (NBO) — definition and investigational context
    DefinitionNormobaric oxygen (NBO) is supplemental oxygen given at normal atmospheric pressure intended to increase oxygen delivery to ischemic brain tissue.
    Investigational contextClinical trials to date are heterogeneous with unclear therapeutic time window; most clinical NBO trials started NBO 6–10 hours after onset and evidence is insufficient to support routine use.
    Research needsFurther preclinical and large clinical studies, including earlier administration (e.g., in ambulance), are needed to determine optimal timing and long-term effects.
    Sonothrombolysis (STL) — definition and investigational/guideline context
    DefinitionSonothrombolysis (STL) uses ultrasound (often combined with microbubbles) to enhance thrombolysis in ischemic stroke.
    Guideline and investigational statusClinical results are controversial and heterogeneous; AHA guidelines do not recommend sonothrombolysis as an adjuvant to IV fibrinolysis and the policy considers microbubbles+ultrasound investigational.
    Evidence gapsSafety data are limited and further in-vivo and clinical studies are needed to define safety/efficacy parameters (e.g., ultrasound settings, MB types).
    Early neurological improvement — definition as used in trials
    DefinitionEarly neurological improvement is a trial-defined measure of clinical improvement at early timepoints (often 24 hours) used to compare thrombolytic agents or interventions.
    Use in trialsMeta-analyses of tenecteplase versus alteplase used early neurological improvement at 24 hours as a primary outcome showing tenecteplase superiority for that early metric in pooled trials.
    InterpretationEarly improvement may predict later functional outcomes but is distinct from 90-day mRS and requires cautious interpretation across heterogeneous studies.
    mRS (duplicate key) — functional outcome measure at 90 days
    DefinitionThe modified Rankin Scale (mRS) at 90 days is the standard functional outcome measure in stroke trials, with scores 0–6 and 0–2 typically indicating good functional outcome (independence).
    Role in trialsTrials of thrombectomy ± IV alteplase commonly use 90-day mRS distribution or proportion with mRS 0–2 as primary endpoints to assess efficacy and non-inferiority/superiority.
    Regulatory/clinical relevancemRS 0–2 at 90 days is used in guideline criteria and coverage-relevant outcome reporting cited in the policy background.
    Non-inferiority margin — definition and relevance to thrombectomy trials
    DefinitionNon-inferiority margin is the pre-specified threshold in trials comparing thrombectomy alone to combined therapy used to judge whether thrombectomy alone is not unacceptably worse than combined treatment.
    Examples citedExamples include OR lower bound 0.8 in Yang et al., absolute margin −10% in Zi et al., and OR margin 0.74 in Suzuki et al.; margins vary across trials and affect interpretation.
    RelevanceDifferences in non-inferiority margins, alteplase dosing, and populations contribute to heterogeneous trial conclusions about thrombectomy-alone strategies.
    Severe basilar artery stenosis (BAS) — definition and threshold
    Definition/thresholdSevere basilar artery stenosis (BAS) is generally described as stenosis greater than or equal to 50%–70% and symptomatic (TIA or ischemic stroke).
    Use in PTAS selectionPTAS in reviewed series was used for severe, symptomatic BAS refractory to dual antiplatelet therapy, often with median baseline stenosis ~81%.
    Clinical implicationDocumentation of percent stenosis, symptoms, and prior medical therapy is emphasized for candidate selection and prior authorization context.
    SNOVA — symptomatic non-acute occlusion of vertebrobasilar artery study description
    Study descriptionSNOVA (symptomatic non-acute occlusion of vertebrobasilar artery) series: single-center retrospective cohort of endovascular recanalization (n=88) with intervals to recanalization 2–89 days (median 23 days) and baseline mRS 2–5 (median 3).
    Outcomes reportedTechnical success rate 92.0%; peri-procedural complication rate 19.3%; mortality 5.7%; follow-up mRS median improved compared with discharge.
    Candidate contextSNOVA patients were symptomatic with lesion characteristics (occlusion length mean 18.3 mm) and were selected for endovascular recanalization in a specialized center setting.

    Policy Dates and References

    Policy status and dates: this Clinical Policy Bulletin is listed as CURRENT. The policy has an effective date of 2009‑07‑10, a last review date of 2023‑11‑07, and a next scheduled review on 2024‑09‑12.

    References: The document includes a compiled list of references supporting the evidence summaries and recommendations; the reference list is provided in the policy's References section.